Core Scientific (CORZ) Cash & Equivalents (2021 - 2026)

Core Scientific (CORZ) has 6 years of Cash & Equivalents data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 44.02% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 44.02% YoY), and the FY2025 full-year result was $311.4 million, down 62.76% from the prior year.
• Cash & Equivalents grew to $1.0 billion in Q1 2026, from $311.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.0 billion in Q1 2026 to a low of $15.9 million in Q4 2022.
• A 5-year average of $282.4 million and a median of $98.1 million in 2024 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 6186.29% in 2022, while the deepest fall reached 86.52% in 2022.
• Tracing CORZ's Cash & Equivalents over 5 years: stood at $15.9 million in 2022, then soared by 217.36% to $50.4 million in 2023, then jumped by 1558.82% to $836.2 million in 2024, then sank by 62.76% to $311.4 million in 2025, then soared by 222.81% to $1.0 billion in 2026.
• Business Quant data shows CORZ's Cash & Equivalents at $1.0 billion in Q1 2026, $311.4 million in Q4 2025, and $453.4 million in Q3 2025.